David S. Ivill is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s New York office. He is the partner-in-charge of the Health Industry Advisory practice in New York. David has extensive experience in statutory and regulatory issues affecting the provision of health care services, particularly with respect to New York State; his practice includes counseling with respect to operational and management issues, fraud and abuse, Medicaid Managed Care, compliance programs, as well as reimbursement matters, corporate practice of medicine issues and not-for-profit/tax-exempt matters. David also has significant experience working with federally qualified health centers and advising clients with respect to the 340B Federal Drug Pricing Program. He represents a range of health care providers including hospitals, physicians and rehabilitation agencies, as well as other health care entities including clinical laboratories and medical device manufacturers. David represents Patient Safety Organizations (PSO) and has developed some of the first PSOs in the country. He also has private equity and mergers and acquisitions experience.
David is listed in Best Lawyers in America and has been recognized by Chambers USA as one of the leading lawyers in his field. He is a member of the American Health Lawyers Association and the Bar of the City of New York.
Prior to practicing law, David was a podiatric surgeon specializing in foot and ankle reconstruction with a subspecialty in oteomyelitis of the lower extremity.
More Legal and Business Bylines From David S. Ivill
- New Challenge to 340B Rule Regarding Orphan Drugs - (Posted On Monday, October 13, 2014)
- 340B Federal Drug Pricing Program September Update: Self-Disclosures - (Posted On Monday, September 15, 2014)
- 340B Registration Changes: Re-enrollment of Currently Participating Facilities and Eligibility Based on Amended Cost Reports - (Posted On Monday, June 23, 2014)
- Federal Court Vacates 340B Rule Regarding Orphan Drugs - (Posted On Monday, June 02, 2014)
- Centers for Medicare & Medicaid Services (CMS) Releases Final Rule Establishing Medicare Prospective Payment System for Federally Qualified Health Center (FQHCs) - (Posted On Wednesday, May 07, 2014)
- Two Recent 340B Developments: New Hospital Registration Guidance and Proposed Rules Under Review at OMB (Office of Management and Budget) - (Posted On Friday, April 11, 2014)
- Office of the Inspector General (OIG) Reports on Contract Pharmacy Arrangements in the 340B Program - (Posted On Wednesday, February 12, 2014)
- Health and Human Services Health Resources and Services Administration (HRSA) Finalizes 340B Program Orphan Drug Exclusion Rules - (Posted On Wednesday, July 24, 2013)
- 340B Drug Pricing Program Notices on Group Purchasing Organizations and Medicaid Exclusion File - (Posted On Thursday, March 28, 2013)
- Change in 340B Program Registration Deadlines - (Posted On Sunday, July 29, 2012)